What happens next following FDA approval of Mounjaro® from Eli Lilly for diabetes?

The FDA on May 13th approved the dual GIP-GLP1-agonist Mounjaro┬« (tirzepatide) from Eli Lilly for diabetes following the completion of the SURPASS studies (e.g. SURPASS-2 NCT03987919). Mounjaro┬« is administered as a weekly injection just like the GLP1-agonist Ozempic┬« (semaglutide) from Novo Nordisk for diabetes. The table below summarizes products from Eli Lilly and Novo Nordisk …

Novo Nordisk 2021Q3 – Wegovy┬« bottlenecks

Novo Nordisk continues to succeed in the GLP-1 space with semaglutide (Ozempic┬«, Rybelsus┬« and Wegovy┬«). Highlights of the quarter include initiation of phase 3a trials with oral semaglutide in obesity and ziltivekimab in cardiovascular disease. Novo Nordisk now has late stage clinical trials in all of their therapy areas. Ozempic┬« continues to be one of …

Novo Nordisk Q2 saw approval of Wegovy® and continued growth of Ozempic® sales

Novo Nordisk sales and operating profit grew at 12% and 9%, respectively, at constant exchange rates. The FDA approved the once-weekly injectable anti-obesity drug Wegovy┬« (semaglutide) on June 4th. The figures below summarize the global sales for Novo Nordisk by geography, by drug and by drug class. All geographic markets have experienced growth, but Victoza┬« …

Novo Nordisk gains GLP-1 market share within and outside the US despite seeing new GLP-1 prescriptions curbed by COVID-19

Novo Nordisk has gained market share in diabetes (29.2%), GLP-1 (49.9%) and insulin (44.5%). The gain in market share has happened with a change in market value in the US as a backdrop; i.e. GLP-1 up and insulin down. As a consequence approximately 70% of sales in the US did not exist 5 years ago. …

Best selling and fastest growing drugs in the 2nd quarter of 2020

Best selling drugs Once more Humira┬« from AbbVie is the best selling drug of the quarter ($4,837M) despite headwinds in Europe from biosimilars Amgevita┬«, Amsparity┬«, Halimatoz┬«, Hefiya┬«, Hulio┬«, Hyrimoz┬«, Idacio┬« and Imraldi┬«. In the US Humira┬« will in 2023 lose market exclusivity to the biosimilars Amjevita┬«, Cyltezo┬«, Hyrimoz┬«, Hadlima┬«, Abrilada┬« and Hulio┬«. AbbVie upon acquisition …

Novo Nordisk grows GLP-1 market share in Q2 in the US with Ozempic® and Rybelsus®

Novo Nordisk has reported their 2nd quarter results. Financials For the 2nd quarter sales were DKKm 30,006 (-0%), gross profit was DKKm 25,234 and operating income was DKKm 13,838 (+3%). In the US GLP1 for diabetes increased by 19%, whereas insulin decreased by 34%. CEO Lars Fruergaard J├Şrgensen “The U.S. sales decline was driven by …

Novo Nordisk mostly unaffected by COVID-19 in Q1

Novo Nordisk is with the exception of the postponement of new clinical trials mostly unaffected by COVID-19. Sales in Q1 were however positively affected by stock piling of insulin. Growth continues to be spearheaded by Ozempic┬«, whereas Victoza┬« and Levemir┬« in the US continue to lead the decline. Rybelsus┬« revenue totaled DKKb 229 in the …

Novo Nordisk poised to fire on all new GLP1 cylinders following the fourth quarter of 2019, but shares fairly valued

Anti-diabetic oral GLP1 drug Rybelsus┬« (semaglutide) received FDA approval on September 20th and 70%-80% of patients are not coming from other injectables. GLP1 drug segment is growing led by the weekly injectable anti-diabetic drug Ozempic┬« (semaglutide) approved for CV risk reduction in the US. Revenue in US diabetes segment is flat due to declining revenue …

Mylan/Viatris and Teva at the 38th Annual J.P. Morgan Healthcare Conference

Mylan presented on Viatris at the 38th Annual J.P. Morgan Healthcare Conference. Below are selected slides from the presentations of Mylan and Teva at the conference and figures comparing the existing business entities prior to the merger with Upjohn. Teva has closed many manufacturing sites, but still have more than Viatris; ~60 and ~50 respectively. …

Keytruda®, Ozempic® and the other blockbuster drugs of the 3rd quarter of 2019

The pharmaceutical companies AbbVie and Novo Nordisk presented their quarterly results today and concluded the earnings season for the major pharmaceutical companies. There are currently more than 50 blockbuster drugs in the world with annual sales exceeding a billion US dollars. Here the best selling and fastest growing medications of the third quarter of 2019 …